{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:55:15Z","timestamp":1790517315489,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T00:00:00Z","timestamp":1481673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.bjhh.2016.09.014","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T20:31:09Z","timestamp":1482438669000},"page":"146-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges"],"prefix":"10.1016","volume":"39","author":[{"given":"Tayse Silva dos","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Sampaio","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Le\u00e3o Cordeiro de","family":"Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bjhh.2016.09.014_bib0305","first-page":"426","article-title":"The many faces of marginal zone lymphoma","volume":"2012","author":"Zinzani","year":"2012","journal-title":"ASH Educ Progr B"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0310","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0315","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"10","key":"10.1016\/j.bjhh.2016.09.014_bib0320","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.5858\/arpa.2014-0291-CC","article-title":"Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings","volume":"138","author":"Behdad","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0330","first-page":"29","article-title":"Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management","volume":"4","author":"Mendes","year":"2014","journal-title":"Blood Lymph Cancer: Targets Therapy"},{"issue":"5","key":"10.1016\/j.bjhh.2016.09.014_bib0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0b013e328349ab8d","article-title":"Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification","volume":"23","author":"Traverse-Glehen","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"17","key":"10.1016\/j.bjhh.2016.09.014_bib0340","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bjhh.2016.09.014_bib0345","first-page":"5019","volume":"117","author":"Campo","year":"2011","journal-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications"},{"issue":"5","key":"10.1016\/j.bjhh.2016.09.014_bib0350","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chac\u00f3n","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bjhh.2016.09.014_bib0355","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","article-title":"Splenic marginal zone lymphoma with or without villous lymphocytes","volume":"101","author":"Iannitto","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/638185","article-title":"Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy","volume":"2012","author":"Arcaini","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0365","first-page":"134","article-title":"Hepatitis C associated B-cell non-hodgkin lymphoma: clinical features and the role of antiviral therapy","volume":"3","author":"Tasleem","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0370","series-title":"Preval\u00eancia da infec\u00e7\u00e3o pelo v\u00edrus da hepatite C em indiv\u00edduos portadores de doen\u00e7as oncohematol\u00f3gicas em Goi\u00e2nia-GO","author":"Marinho","year":"2013"},{"issue":"8","key":"10.1016\/j.bjhh.2016.09.014_bib0375","first-page":"657","article-title":"Prevalence of hepatitis C infection in patients with non-Hodgkin's lymphomas","volume":"9","author":"Chindamo","year":"2002","journal-title":"Oncol Rep"},{"issue":"48","key":"10.1016\/j.bjhh.2016.09.014_bib0380","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the interlymph non-Hodgkin lymphoma subtypes project","volume":"2014","author":"Bracci","year":"2014","journal-title":"JNCI Monogr"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0385","series-title":"Non-Hodgkin lymphoma","first-page":"227","article-title":"Management of the marginal zone lymphomas","author":"Vannata","year":"2015"},{"issue":"12","key":"10.1016\/j.bjhh.2016.09.014_bib0395","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0605","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ajcp\/108.4.378","article-title":"Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8(CD79b)","volume":"108","author":"Moreau","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0405","series-title":"Non-Hodgkin lymphoma","author":"Evens","year":"2015"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0390","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"issue":"11\/12","key":"10.1016\/j.bjhh.2016.09.014_bib0410","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/0145-2126(95)00165-4","article-title":"The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders","volume":"20","author":"Salomon-Nguyen","year":"1996","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","article-title":"Italian society of hematology, italian society of experimental hematology, and italian group for bone marrow transplantation guidelines for the management of indolent, nonfollicular b-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic)","volume":"15","author":"Tarella","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.bjhh.2016.09.014_bib0420","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2559.2012.04289.x","article-title":"IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas","volume":"61","author":"Falini","year":"2012","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0425","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/AJCPKUM9J4IXCWEU","article-title":"Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders","volume":"136","author":"Venkataraman","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bjhh.2016.09.014_bib0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","volume":"44","author":"Perrone","year":"2016","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.bjhh.2016.09.014_bib0435","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","article-title":"Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions","volume":"100","author":"Schop","year":"2002","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bjhh.2016.09.014_bib0440","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2013-04-494849","article-title":"A new era for Waldenstrom macroglobulinemia: MYD88 L265P","volume":"121","author":"Treon","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0445","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0002-9440(10)64988-7","article-title":"Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas","volume":"156","author":"Remstein","year":"2000","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.bjhh.2016.09.014_bib0450","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood.V90.10.4071","article-title":"Preferential dissemination of B-cell gastric mucosa-associated lymphoid tissue (MALT) lymphoma to the splenic marginal zone","volume":"90","author":"Du","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bjhh.2016.09.014_bib0455","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0460","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bjhh.2016.09.014_bib0465","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bjhh.2016.09.014_bib0470","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bjhh.2016.09.014_bib0475","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0480","first-page":"194","article-title":"Splenic marginal zone lymphoma: current knowledge and future directions","volume":"26","author":"Thieblemont","year":"2012","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0485","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","article-title":"The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma","volume":"158","author":"Hockley","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bjhh.2016.09.014_bib0490","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/17474086.2013.845522","article-title":"Splenic marginal zone lymphoma: disease features and management","volume":"6","author":"Matutes","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0495","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.bjhh.2016.09.014_bib0500","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bjhh.2016.09.014_bib0505","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood.V97.11.3552","article-title":"p53 abnormalities in splenic lymphoma with villous lymphocytes","volume":"97","author":"Gruszka-Westwood","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bjhh.2016.09.014_bib0510","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s12885-015-1766-z","article-title":"Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations","volume":"15","author":"Peveling-Oberhag","year":"2015","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0515","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalb\u00e1n","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0520","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bjhh.2016.09.014_bib0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0530","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0535","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.12036","article-title":"Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma","volume":"159","author":"Else","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.bjhh.2016.09.014_bib0540","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2010-09-271437","article-title":"How I diagnose and treat splenic lymphomas","volume":"117","author":"Iannitto","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bjhh.2016.09.014_bib0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin Hematol"},{"issue":"Suppl. 2","key":"10.1016\/j.bjhh.2016.09.014_bib0550","first-page":"168","article-title":"Splenectomy versus Rituximab in the treatment of splenic marginal zone lymphoma","volume":"94","author":"Kalpadakis","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bjhh.2016.09.014_bib0555","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/annonc\/mdt181","article-title":"Significant efficacy of 2-chlorodeoxyadenosine+rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up","volume":"24","author":"Cervetti","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bjhh.2016.09.014_bib0595","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","article-title":"Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.bjhh.2016.09.014_bib0560","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bjhh.2016.09.014_bib0565","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bjhh.2016.09.014_bib0570","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0575","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.bjhh.2016.09.014_bib0580","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.bjhh.2016.09.014_bib0585","first-page":"45","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy","volume":"149","author":"Bennett","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bjhh.2016.09.014_bib0590","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bjhh.2016.09.014_bib0600","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1046\/j.1365-2141.1998.1161f.x","article-title":"Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes","volume":"103","author":"El Weshi","year":"1998","journal-title":"Br J Haematol"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848416301311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848416301311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T01:22:40Z","timestamp":1601256160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848416301311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1516848416301311"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2016.09.014","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2016.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}